Verrica Pharmaceuticals Inc. (VRCA)
Develops skin disease treatments, including a wart and molluscum cure.
$5.40+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-4.3%
The outlook
Verrica trades near the lower end of its 52-week range, well below its 50- and 200-day moving averages. Analyst consensus is solidly bullish with an average price target roughly 188% above current levels, though the stock has drifted lower recently. The overall sentiment sits neutral, reflecting a gap between analyst views and recent price action.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range32% of the way from its 52-week low to high
Price targetAvg target +188% vs current price
Analyst price target
~12-month · 5 analysts$15.54average target+187.9% vs now
Now $5.40
Low $10.00High $20.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$92.8M
52-wk high
$9.82
52-wk low
$3.28
50-day avg
$5.94
200-day avg
$6.07
Trailing P/E
—